Mitomycin C plus cisplatin for systemic treatment of recurrent BRCA1-associated ovarian cancer
{{output}}
Background Previous studies on neoadjuvant therapy for BRCA1-driven ovarian cancer (OC) demonstrated higher efficacy of mitomycin C plus cisplatin combination as compared to standard drug schemes. These data call for evaluation of the utility of this regimen f... ...
